Abstract

The catecholamine neurotransmitter dopamine has the potential to act as an endogenous neurotoxin when its vesicular sequestration is dysregulated. Despite postmortem analyses from patients with Parkinson’s disease that demonstrate decreased vesicular sequestration of dopamine with a corresponding increase in dopamine metabolism, dopamine’s contribution to nigrostriatal dopaminergic degeneration in Parkinson’s disease has been debated. Here, we present a new in vivo model demonstrating the induction of Parkinson’s disease-associated pathogenic mechanisms of degeneration resulting from acquired dysregulation of dopamine sequestration in nigrostriatal dopaminergic neurons in adult rats. Utilizing adeno-associated virus (serotype 2), viral-mediated small-hairpin RNA interference of endogenous vesicular monoamine transporter 2 (VMAT2) expression resulted in a loss of VMAT2 protein expression in transduced dopaminergic cell bodies in the substantia nigra with a corresponding loss of VMAT2 protein within the striatal terminals. The loss of VMAT2 resulted in an accumulation of cytosolic dopamine and subsequent increased dopamine metabolism, deficits in dopamine-mediated behaviors, and degeneration of nigrostriatal dopaminergic neurons that was rescued through reintroduction of exogenous VMAT2, demonstrating that the toxicity was specific to the loss of VMAT2. Analysis of parkinsonian pathogenic mechanisms of degeneration identified oxidative damage, activation of Parkinson’s disease-associated kinase LRRK2, and the formation of aberrant α-synuclein. This model demonstrates that a progressive acquired loss of VMAT2 expression in adulthood is sufficient to induce Parkinson’s disease-associated pathogenic mechanisms of degeneration and provides a new model to further investigate the consequences of cytosolic dopamine.

Highlights

  • Parkinson’s disease is a progressive neurodegenerative disease characterized by motor deficits resulting from the degeneration of dopaminergic neurons in the nigrostriatal pathway

  • The vesicular monoamine transporter 2 (VMAT2) was targeted by ribonucleic acid interference using a short-hairpin RNA in a dopaminergic neuronal cell line (RCSN-3) derived from the midbrain of an adult rat as the initial step to test the feasibility of knockingdown VMAT2 expression in adult animals

  • Transfections with shVMAT2 were performed with coadministration of green fluorescent protein (GFP) to identify transfected cells, and efficiency of shVMAT2-mediated knockdown was quantified compared to cells transfected with a scramble short-hairpin RNA (shRNA)

Read more

Summary

Introduction

Parkinson’s disease is a progressive neurodegenerative disease characterized by motor deficits resulting from the degeneration of dopaminergic neurons in the nigrostriatal pathway. Parkinson’s disease cases resulting solely from genetic factors are rare, and the majority of cases are believed to be the result of complex interactions between predisposition genes, a lifetime accumulation of environmental exposures, and deficits due to normal aging processes[1,2,3]. While multiple neuronal populations are affected in Parkinson’s disease, the nigrostriatal dopaminergic neurons appear to have increased vulnerability to degeneration and the loss of these neurons results in the cardinal motor symptoms that lead to a diagnosis of Parkinson’s disease. It is hypothesized that dopamine, the neurotransmitter these neurons use to regulate motor output, contributes to the vulnerability to degeneration; this is thought to be due to dopamine’s potential to act as an endogenous neurotoxin through two processes that generate reactive metabolites and reactive oxygen species: oxidation and enzymatic catabolism[4]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call